Drug Trial Radar · NCT00894699
A Study to Evaluate the Clinical Efficacy, Safety and Tolerability of ARX-F03 Sublingual Sufentanil/Triazolam NanoTab™ in Patients Undergoing an Elective Abdominal Liposuction Procedure
Last checked: Nov 20, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Jun 2009
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Talphera, IncIndustry
- Sponsor type
- Industry
- First posted
- May 7, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and effectiveness of a study medication that contains a combination of a pain medication, sufentanil, and a sedative, triazolam. This drug is being designed to provide mild sedation as well as reduce anxiety and pain before and during a procedure (in this case elective abdominal liposuction).
Conditions
- Sedation
- Anxiety
- Pain
Interventions
Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)Drug
Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
Placebo NanoTab™Drug
Single dose of sublingual placebo NanoTab™
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summed Richmond Agitation Sedation Score (RASS) Over the 4-hour Study Period (SRS-4)Time frame: 4 hour study period
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lotus Clinical Research, Inc.
Pasadena, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.